Skip to main content
Fig. 2 | Molecular Cancer

Fig. 2

From: A liquid biopsy signature predicts treatment response to fluoropyrimidine plus platinum therapy in patients with metastatic or unresectable gastric cancer: implications for precision oncology

Fig. 2

The 2-miRNA biomarker panel predicts chemo-responsiveness and prognosis in patients with mGC. A A ROC curve shows the accuracy of the 2-miRNA biomarker panel for predicting responsiveness to systemic chemotherapy (responder group vs. non-responder group). B A waterfall plot illustrates the ability of the biomarker panel to identify responders. C A ROC curve shows the ability of the 2-miRNA biomarker panel to successfully identify patients with progressive disease on first-line chemotherapy. D A response-probability score derived from the biomarker model was significantly different between responder vs. non-responder groups (** P < 0.01). E A Kaplan-Meier curve indicates a significant difference in median progression-free survival (PFS) between patients grouped as having a high- vs. low-probability for response to chemotherapy, determined by the cutoff values derived from the response-prediction model. E A Kaplan-Meier curve indicates a significant difference in overall survival (OS) between the two groups

Back to article page

Molecular Cancer

ISSN: 1476-4598